Amorfix Life Sciences and CNJ Holdings have signed an agreement to identify and develop therapeutic antibodies targeting disease specific epitopes (DSEs). The collaboration will make use of Amorfix's ProMIS discovery technology and the ...
Tags: Amorfix Life Sciences, CNJ Holdings, agreement, disease specific epitopes